

Jan Delaval

98817

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jennifer Kim Examiner #: 77469 Date: 7/15/03
Art Unit: 1617 Phone Number 301 8-2232 Serial Number: 101046729
Mail Box and Bldg/Room Location: 201A Results Format Preferred (circle): PAPER DISK E-MAIL

²⁸¹⁹
If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Treatment of sleep disturbance
Inventors (please provide full names): Koch et al.

Earliest Priority Filing Date: 1/19/01

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

1) Please search claims 1 - 13

RECEIVED
JUL 15 2003
(STIC)

THY

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>[Signature]</u>	NA Sequence (#) _____	STN <u>✓</u>
Searcher Phone #: <u>4458</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>7/16/03</u>	Bibliographic <u>✓</u>	Dr.Link _____
Date Completed: <u>7/16/03</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>15</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>+45</u>	Other _____	Other (specify) _____



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 98817

TO: Jennifer Kim
Location: 2d17 / 2b19
Wednesday, July 16, 2003
Art Unit: 1617
Phone: 308-2232
Serial Number: 10 / 046727

From: Jan Delaval
Location: Biotech-Chem Library
CM1-1E07
Phone: 308-4498

jan.delaval@uspto.gov

Search Notes

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov



STIC SEARCH RESULTS

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 - Circ. Desk



=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 17:09:43 QN 16 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
Civ 11E07-703-308-4498
jan.delaval@uspto.gov

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2003 VOL 139 ISS 3

FILE LAST UPDATED: 15 Jul 2003 (20030715/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 198

L98 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2003 ACS

AN 2003:117637 HCAPLUS

DN 138:158841

TI Sucralose formulations to mask unpleasant tastes

IN Jaeger, David; Dickerson, Jay; Mogavero, Annabelle

PA **Wyeth, John, and Brother Ltd., USA**

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-715

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011306	A1	20030213	WO 2002-US24298	20020731
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2001-308912P P 20010731

AB The present invention is directed to a pharmaceutically acceptable taste masking liq. excipient base for administration of a relatively large amt. of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addn. of sucralose to the excipient base with maintenance of a pH 2-5. The invention is further directed to medicinal compns. comprising such a liq. excipient base and unpleasant tasting medicines. Still further, the invention is directed to a method for taste masking unpleasant tasting medicines through their incorporation into the claimed liq. excipient bases. A

cough syrup ,contained guaifenesin 2.00, pseudoephedrine-HCl 0.60, dextromethorphan-HBr 0.20, PEG-1450 20.00, glycerin 6.00, high-fructose corn syrup (55%) 45.00, anhyd. citric acid 1.60, and 70% sorbitol 5.00, sodium citrate 0.20, sodium benzoate 0.30, Red No. 40 dye 0.05, golden punch flavor 0.10, sucralose 0.20, and water to 100.0%.

ST sucralose formulation unpleasant taste masking

IT Anti-inflammatory agents

(nonsteroidal; sucralose formulations to mask unpleasant tastes)

IT Analgesics

Antibiotics

Antihistamines

Antitumor agents

Antitussives

Bitterness

Decongestants

Expectorants

Human

(sucralose formulations to mask unpleasant tastes)

IT Drug delivery systems

(syrups, cough; sucralose formulations to mask unpleasant tastes)

IT 52-28-8, Codeine phosphate **58-73-1, Diphenhydramine**

59-33-6, Pyrillamine 59-42-7, Phenylephrine 77-22-5, Caramiphen

86-22-6, Brompheniramine 91-81-6, Tripelenamine 93-14-1, Guaifenesin

103-90-2, Acetaminophen 113-92-8, Chlorpheniramine maleate 118-23-0,

Bromodiphenhydramine 125-69-9, Dextromethorphan hydrobromide 129-03-3,

Cyproheptadine 132-21-8, DexBrompheniramine 345-78-8, Pseudoephedrine

hydrochloride 486-12-4, Triprolidine 562-10-7, Doxylamine 569-59-5,

Phenindamine 980-71-2, Brompheniramine maleate 1321-14-8, Potassium

guaicolsulfonate 1420-53-7, Codeine sulfate 2451-01-6, Terpin hydrate

3964-81-6, Azatadine 7681-11-0, Potassium iodide (KI), biological

studies 7778-49-6, Potassium citrate 14838-15-4, Phenylpropanolamine

15687-27-1, Ibuprofen 22071-15-4, Ketoprofen

22204-53-1, Naproxen 25523-97-1, DexChlorpheniramine 56038-13-2,

Sucralose

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sucralose formulations to mask unpleasant tastes)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Blase; US 5409907 A 1995 HCAPLUS

(2) Cherukuri; US 5013716 A 1991 HCAPLUS

IT **58-73-1, Diphenhydramine 15687-27-1,**

Ibuprofen

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sucralose formulations to mask unpleasant tastes)


RN 58-73-1 HCAPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)

Ph₂CH-O-CH₂-CH₂-NMe₂

RN 15687-27-1 HCAPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)




L98 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS
 AN 2002:555345 HCAPLUS
 DN 137:103930
 TI **Ibuprofen-diphenhydramine** composition and method for
 the treatment of pain-associated **sleep** disturbances
 IN **Cooper, Stephen Allen; Doyle, Geraldine Ann;**
Cook, Graham David; Koch, Todd Shawn; Fort, James
Joseph; Bianco, Giustino; Giamalva, David Hugh
 PA **Wyeth, John, and Brother Ltd., USA**
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002056877	A1	20020725	WO 2002-US3855	20020118	<--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002177626	A1	20021128	US 2002-46727	20020117	<--
PRAI	US 2001-262387P	P	20010119			<--
AB	The invention provides a compn. for treating pain-assocd. sleep disturbances, esp. shortened sleep duration, comprising ibuprofen and diphenhydramine . The compn. is further prepd. as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule compn., to prevent interaction between the active ingredients.					
ST	ibuprofen diphenhydramine pharmaceutical pain assocd sleep disturbance treatment					
IT	Drug delivery systems (caplets; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)					
IT	Drug delivery systems (capsules; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)					
IT	Sleep (disorder ; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)					
IT	Analgesics Drug delivery systems Drug interactions Human					

Pain

- (**ibuprofen-diphenhydramine** compn. and method for treatment of pain-assocd. **sleep** disturbances)
- IT **Polyoxyalkylenes**, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**ibuprofen-diphenhydramine** compn. and method for treatment of pain-assocd. **sleep** disturbances)
- IT Surgery
 (oral; **ibuprofen-diphenhydramine** compn. and method for treatment of pain-assocd. **sleep** disturbances)
- IT Drug delivery systems
 (tablets, bilayer; **ibuprofen-diphenhydramine** compn. and method for treatment of pain-assocd. **sleep** disturbances)
- IT **58-73-1, Diphenhydramine 147-24-0, Diphenhydramine hydrochloride 15687-27-1, Ibuprofen 88637-37-0, Diphenhydramine citrate**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**ibuprofen-diphenhydramine** compn. and method for treatment of pain-assocd. **sleep** disturbances)
- IT **25322-68-3, Polyethylene glycol**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**ibuprofen-diphenhydramine** compn. and method for treatment of pain-assocd. **sleep** disturbances)
- RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Cevc Gregor; EP 0475160 A 1992 HCAPLUS
 - (2) Charles, F; WO 9729735 A 1997 HCAPLUS
 - (3) Drizen, A; US 6063405 A 2000 HCAPLUS
 - (4) Lam Pharmaceuticals Inc; WO 9711681 A 1997 HCAPLUS
 - (5) Sunshine, A; US 4522826 A 1985 HCAPLUS
 - (6) Sunshine, A; US 4985459 A 1991 HCAPLUS
- IT **58-73-1, Diphenhydramine 147-24-0, Diphenhydramine hydrochloride 15687-27-1, Ibuprofen 88637-37-0, Diphenhydramine citrate**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**ibuprofen-diphenhydramine** compn. and method for treatment of pain-assocd. **sleep** disturbances)
- RN 58-73-1 HCAPLUS
- CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)




- RN 147-24-0 HCAPLUS
- CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



HCl


- RN 15687-27-1 HCAPLUS
- CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 88637-37-0 HCAPLUS
 CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 77-92-9
 CMF C6 H8 O7




CM 2

CRN 58-73-1
 CMF C17 H21 N O



IT 25322-68-3, **Polyethylene glycol**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ibuprofen-diphenhydramine compn. and method for
 treatment of pain-assocd. **sleep** disturbances)
 RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L98 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2003 ACS
 AN 2002:157572 HCAPLUS
 DN 136:189396
 TI **Ibuprofen** solutions for **capsule**-filling and **capsule** preparations
 IN Kato, Soichiro; Tsumori, Katsuyuki; Shinoda, Yasuo; Inagi, Toshio
 PA Kowa Company, Ltd., Japan
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent

LA Japanese
 IC ICM A61K031-192
 ICS A61K009-08; A61K009-48; A61K047-34; A61K047-10; A61K047-06;
 A61K047-08

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015900	A1	20020228	WO 2001-JP7223	20010823 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001080124	A5	20020304	AU 2001-80124	20010823 <--
	EP 1321140	A1	20030625	EP 2001-958434	20010823 <--
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	JP 2000-255827	A	20000825 <--		
	WO 2001-JP7223	W	20010823		
AB	Capsule prepsns. are produced by using solns. for capsule				
	-filling which contain ibuprofen, polyethylene glycol , water and terpenes (menthol, limonene, borneol, dl-camphor, mentha oil, etc.) optionally together with one or more drugs selected from among antipyretic analgesics, antihistamines, antitussives, expectorants, sympathetic stimulants, analeptics, hypnotic sedatives and anti-inflammatory agents, solubilizers, thickeners, pH controlling agents, colorants, etc. Thus, it is attempted to relieve the bitterness of ibuprofen and establish an immediate action at the same time.				
ST	capsule ibuprofen PEG terpene				
IT	Antipyretics				
	(analgesic; capsules contg. ibuprofen and PEG and terpenes and other drugs)				
IT	Analgesics				
	(antipyretic; capsules contg. ibuprofen and PEG and terpenes and other drugs)				
IT	Anti-inflammatory agents				
	Antihistamines				
	Antitussives				
	Expectorants				
	Hypnotics and Sedatives				
	Nervous system stimulants				
	(capsules contg. ibuprofen and PEG and terpenes and other drugs)				
IT	Polyoxyalkylenes , biological studies				
	Terpenes, biological studies				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(capsules contg. ibuprofen and PEG and terpenes and other drugs)				
IT	Drug delivery systems				
	(capsules; capsules contg. ibuprofen and PEG and terpenes and other drugs)				
IT	Essential oils				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(mint, Mentha; capsules contg. ibuprofen and PEG and terpenes and other drugs)				
IT	Nerve				
	(sympathetic, stimulants; capsules contg. ibuprofen and PEG and terpenes and other drugs)				

IT 58-08-2, Caffeine, biological studies 76-22-2, dl-Camphor 89-78-1, Menthol 93-14-1, Guaifenesin, 113-92-8, Chlorpheniramine maleate 125-69-9, Dextromethorphan hydrobromide 138-86-3, Limonene 147-24-0, Diphenhydramine hydrochloride 507-70-0, Borneol 912-60-7, Noscapine hydrochloride 15687-27-1, Ibuprofen 18760-80-0, dl-Methylephedrine hydrochloride 24204-13-5, Dihydrocodeine phosphate 25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (capsules contg. ibuprofen and PEG and terpenes and other drugs)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

- (1) Consumer Health S A; ZA 9706189 A 1998 HCAPLUS
- (2) Consumer Health S A; ZA 9706189 A 1998 HCAPLUS
- (3) Consumer Health S A; AU 9734442 A 1998 HCAPLUS
- (4) Consumer Health S A; AU 9734442 A 1998 HCAPLUS
- (5) Consumer Health S A; WO 9802182 A1 1998 HCAPLUS
- (6) Consumer Health S A; WO 9802182 A1 1998 HCAPLUS
- (7) R P Scherer Corporation; JP 01502185 A 1988
- (8) R P Scherer Corporation; EP 293406 A1 1988 HCAPLUS
- (9) R P Scherer Corporation; US 5071643 1988 HCAPLUS
- (10) R P Scherer Corporation; US 5360615 1988 HCAPLUS
- (11) R P Scherer Corporation; ZA 8708723 A 1988 HCAPLUS
- (12) R P Scherer Corporation; AU 8781573 A 1988 HCAPLUS
- (13) R P Scherer Corporation; WO 8802625 A1 1988 HCAPLUS
- (14) Taisho Pharmaceutical Co Ltd; JP 08333246 A 1996 HCAPLUS
- (15) Taisho Pharmaceutical Co Ltd; US 5827852 A 1996 HCAPLUS
- (16) The Procter & Gamble Company; JP 08509725 A 1994
- (17) The Procter & Gamble Company; US 5827852 A 1994 HCAPLUS
- (18) The Procter & Gamble Company; EP 695175 A1 1994 HCAPLUS
- (19) The Procter & Gamble Company; WO 9425009 A1 1994 HCAPLUS
- (20) The Procter & Gamble Company; NO 9504146 A 1994 HCAPLUS
- (21) The Procter & Gamble Company; FI 9505144 A 1994 HCAPLUS

IT 147-24-0, Diphenhydramine hydrochloride 15687-27-1, Ibuprofen 25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (capsules contg. ibuprofen and PEG and terpenes and other drugs)

RN 147-24-0 HCAPLUS


CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Ph2CH-O-CH2-CH2-NMe2


● HCl

RN 15687-27-1 HCAPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L98 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2003 ACS
 AN 1999:27707 HCAPLUS
 DN 130:86181
 TI Pharmaceutical formulations containing **ibuprofen** and **diphenhydramine** analgesics
 IN Hough, Douglas R.; Nelson, Edward B.; Raffa, Robert B.
 PA McNeil-PPC, USA
 SO PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-19
 ICS A61K031-135; A61K031-19; A61K031-135
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9858640	A1	19981230	WO 1997-US10857	19970623 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9743256	A1	19990104	AU 1997-43256	19970623 <--
PRAI	WO 1997-US10857		19970623 <--		
AB	Disclosed are compns. comprising ibuprofen (I) and diphenhydramine (II) and methods for their use in analgesia. When ibuprofen and diphenhydramine are within certain ratios, their pharmacol. effects are superadditive. ED50 of I and II.HCl decreased from 36.5 and 8.0 mg/kg, resp. to 2.4 mg/kg orally each, when, combined and none of the mice tested in acetylcholine bromide induced abdominal constriction assay showed writhing.				
ST	pharmaceutical formulation ibuprofen diphenhydramine synergism analgesic				
IT	Alcohols, biological studies				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C16-18; pharmaceutical formulations contg. ibuprofen and diphenhydramine analgesics)				

- IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyl dimethyl, chlorides; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT **Polyoxyalkylenes**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylene derivs.; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT Emulsifying agents
(anionic; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters, with **polyoxyethylene** sorbitan; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT Emulsifying agents
(nonionic; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT Acacia
Antihistamines
(pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT Lanolin
Lecithins
Paraffin oils
Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT Analgesics
(synergistic; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT **58-73-1, Diphenhydramine 15687-27-1, Ibuprofen**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
- IT 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-88-5, Cholest-5-en-3-ol (3.beta.)-, biological studies 102-71-6, Triethanolamine, biological studies 111-42-2, biological studies 112-80-1, Oleic acid, biological studies 120-51-4, Benzylbenzoate 121-54-0 141-43-5, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 577-11-7, Docusate sodium 7558-79-4 8044-71-1, Cetrимide 9002-89-5 9004-64-2, Hydroxypropyl cellulose 9004-67-5, Methylcellulose 9004-99-3, **Polyoxyethylene** stearate 9005-32-7, Alginic acid 9005-63-4D, **Polyoxyethylene** sorbitan, esters with fatty acids 12441-09-7D, Sorbitan, esters 12619-70-4, Cyclodextrin **25322-68-3D**, alkylene derivs. 25496-72-4, Glyceryl monooleate 31566-31-1, Glyceryl monostearate 36653-82-4, Cetyl alcohol 106392-12-5, Poloxamer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Motola, S; US 5024997 A 1991 HCAPLUS

- (2) Richardson Vicks Inc; US 4522826 1985 HCAPLUS
 (3) Richardson Vicks Inc; WO 8503443 A 1985 HCAPLUS


IT 58-73-1, **Diphenhydramine 15687-27-1,**
Ibuprofen

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulations contg. **ibuprofen** and
diphenhydramine analgesics)


RN 58-73-1 HCAPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 15687-27-1 HCAPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)




IT 25322-68-3D, alkylene derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations contg. **ibuprofen** and
diphenhydramine analgesics)

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L98 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2003 ACS

AN 1991:589755 HCAPLUS

DN 115:189755

TI Pharmaceutical composition and methods for treating the symptoms of overindulgence

IN Goldman, William J.; Gates, Thomas N.

PA McNeil-PPC, Inc., USA

SO Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K031-415

ICS A61K031-34; A61K031-165; A61K031-19; A61K031-44

ICI A61K031-415, A61K031-19, A61K031-165; A61K031-34, A61K031-165;

A61K031-165, A61K031-135; A61K031-19, A61K031-135; A61K031-44, A61K031-19, A61K031-165

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 426479	A1	19910508	EP 1990-311995	19901101
	EP 426479	B1	19940216		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI				
	IN 171746	A	19921226	IN 1990-CA907	19901029
	CA 2028746	AA	19910503	CA 1990-2028746	19901031
	CA 2028746	C	19951226		
	AU 9065689	A1	19910509	AU 1990-65689	19901031
	AU 646230	B2	19940217		
	ZA 9008775	A	19920729	ZA 1990-8775	19901101
	AT 101515	E	19940315	AT 1990-311995	19901101
	ES 2057439	T3	19941016	ES 1990-311995	19901101
	JP 03206052	A2	19910909	JP 1990-298713	19901102
	US 5204118	A	19930420	US 1992-876824	19920429
	IN 176327	A	19960427	IN 1992-CA757	19921016
	US 5417980	A	19950523	US 1994-268865	19940629
PRAI	US 1989-430837	A	19891102		
	IN 1990-CA907	A1	19901029		
	EP 1990-311995	A	19901101		
	US 1992-876824	A3	19920429		
	US 1993-46534	B1	19930413		
AB	Pharmaceutical compns. which can relieve the symptoms of overindulgence, such as headache and acid indigestion, comprise (1) acetaminophen or a nonsteroidal antiinflammatory drug and (2) histamine H1 or H2 receptor blocker, proton pump inhibitor, or a combination thereof. The compn. can be in the form of tablets, capsules, or liqs. Thus, a tablet contained acetaminophen 500, cimetidine 150 mg, and other auxiliary agents and coloring agents.				
ST	overeating symptom antiinflammatory antihistaminic tablet; acetaminophen cimetidine tablet overeating symptom				
IT	Headache (from overeating, treatment of, inflammation inhibitor-antihistaminic combinations for)				
IT	Inflammation inhibitors (mixts. with antihistaminics, headache and indigestion from overeating treatment with)				
IT	Antacids and Antiflatulents (mixts. with inflammation inhibitors, headache and indigestion from overeating treatment with)				
IT	Antihistaminics (H1, mixts. with inflammation inhibitors, headache and indigestion from overeating treatment with)				
IT	Antihistaminics (H2, mixts. with inflammation inhibitors, headache and indigestion from overeating treatment with)				
IT	Digestive tract (disease, indigestion, from overeating, treatment of, inflammation inhibitor-antihistaminic combinations for)				
IT	Appetite (disorder, hyperphagia, discomfort from, treatment of, inflammation inhibitor-antihistaminic combinations for)				
IT	Pharmaceutical dosage forms (liqs., oral, of anti-inflammatory and antihistaminic combinations, for treatment of headache and indigestion from overeating)				
IT	Pharmaceutical dosage forms (tablets, of anti-inflammatory and antihistaminic combinations, for treatment of headache and indigestion from overeating)				
IT	53-86-1D, mixts. with antihistaminics 58-73-1D, mixts. with anti-inflammatory agent 59-33-6D, Pyrilamine, mixts. with anti-inflammatory agent 60-87-7D, Promethazine, mixts. with anti-inflammatory agent 61-68-7D, mixts. with antihistaminics 68-88-2D, Hydroxyzine, mixts. with anti-inflammatory agent 79-09-4D,				

Propanoic acid, derivs., mixts. with antihistaminics 82-92-8D,
 Cyclizine, mixts. with anti-inflammatory agent 91-40-7D, Fenamic acid,
 derivs., mixts. with antihistaminics 91-81-6D, Tripelenamine, mixts.
 with anti-inflammatory agent 103-90-2D, Acetaminophen, mixts. with
 antihistaminics 113-92-8D, Chlorpheniramine, mixts. with
 anti-inflammatory agent 486-16-8D, Carbinoxamine, mixts. with
 anti-inflammatory agent 523-87-5D, mixts. with anti-inflammatory agent
 569-65-3D, Meclizine, mixts. with anti-inflammatory agent 644-62-2D,
 mixts. with antihistaminics 15687-27-1D, Ibuprofen, mixts. with
 antihistaminics 22071-15-4D, mixts. with antihistaminics 22204-53-1D,
 mixts. with antihistaminics 26171-23-3D, Tolmetin, mixts. with
 antihistaminics 29679-58-1D, Fenoprofen, mixts. with antihistaminics
 32536-43-9D, Indole acetic acid, derivs., mixts. with antihistaminics
 36322-90-4D, Piroxicam, mixts. with antihistaminics 38194-50-2D,
 Sulindac, mixts. with antihistaminics 51481-61-9D, Cimetidine, mixts.
 with anti-inflammatory agent 66357-35-5D, Ranitidine, mixts. with
 anti-inflammatory agent 73590-58-6D, mixts. with anti-inflammatory agent
 76824-35-6D, mixts. with anti-inflammatory agent 136584-95-7
 136584-96-8 136584-97-9 136584-98-0 136584-99-1 136585-00-7
 136585-01-8 136585-02-9 136585-03-0 136585-04-1 136585-05-2
 136585-06-3 136585-07-4 **136585-08-5**

RL: BIOL (Biological study)

(headache and indigestion from overeating treatment with)

IT **136585-08-5**

RL: BIOL (Biological study)

(headache and indigestion from overeating treatment with)


RN 136585-08-5 HCAPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, mixt. with
 2-(diphenylmethoxy)-N,N-dimethylethanamine (9CI) (CA INDEX NAME)

CM 1

CRN 15687-27-1


CMF C13 H18 O2



CM 2

CRN 58-73-1

CMF C17 H21 N O



=> sel hit rn 198

E7 THROUGH E12 ASSIGNED

=> fil reg;s e7-e12

FILE 'REGISTRY' ENTERED AT 17:09:58 ON 16 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2003 HIGHEST RN 548735-19-9
DICTIONARY FILE UPDATES: 15 JUL 2003 HIGHEST RN 548735-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


1 15687-27-1/BI
 (15687-27-1/RN)
1 25322-68-3/BI
 (25322-68-3/RN)
1 58-73-1/BI
 (58-73-1/RN)
1 147-24-0/BI
 (147-24-0/RN)
1 136585-08-5/BI
 (136585-08-5/RN)
1 88637-37-0/BI
 (88637-37-0/RN)
L99 6 (15687-27-1/BI OR 25322-68-3/BI OR 58-73-1/BI OR 147-24-0/BI OR
 136585-08-5/BI OR 88637-37-0/BI)

=> d ide can tot

L99 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2003 ACS
RN 136585-08-5 REGISTRY
CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, mixt. with
2-(diphenylmethoxy)-N,N-dimethylethanamine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, mixt. contg. (9CI)
MF C17 H21 N O . C13 H18 O2
CI MXS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 15687-27-1
CMF C13 H18 O2



CM 2

CRN 58-73-1

CMF C17 H21 N O



1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 115:189755

L99 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN 88637-37-0 REGISTRY

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Diphenhydramine citrate

MF C17 H21 N O . C6 H8 O7

CI COM

SR Commission of European Communities

LC STN Files: BEILSTEIN*, BIOBUSINESS, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN, IPA, PROMT, TOXCENTER, USAN, USPATFULL

(*File contains numerically searchable property data)


Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 77-92-9


CMF C6 H8 O7



CM 2

CRN 58-73-1

CMF C17 H21 N O



15 REFERENCES IN FILE CA (1957 TO DATE)
15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:103930

REFERENCE 2: 137:11003

REFERENCE 3: 135:262242

REFERENCE 4: 132:255811

REFERENCE 5: 129:265468

REFERENCE 6: 129:127191

REFERENCE 7: 127:55916

REFERENCE 8: 124:298541

REFERENCE 9: 121:42500

REFERENCE 10: 120:307174

L99 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN **25322-68-3** REGISTRY

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN .alpha.,.omega.-Hydroxypoly(ethylene oxide)

CN .alpha.-Hydro-.omega.-hydroxypoly(oxy-1,2-ethanediyl)

CN .alpha.-Hydro-.omega.-hydroxypoly(oxyethylene)

CN 1,2-Ethanediol, homopolymer

CN 16600

CN 1660S

CN 400DAB8

CN Alkox

CN Alkox E 100

CN Alkox E 130

CN Alkox E 160

CN Alkox E 240

CN Alkox E 30

CN Alkox E 45

CN Alkox E 60

CN Alkox E 75

CN Alkox R 1000

CN Alkox R 15

CN Alkox R 150

CN Alkox R 400

CN Alkox SR

CN Antarox E 4000

CN Aquacide III

CN Aquaffin

CN Badimol

CN BDH 301

CN Bradsyn PEG

CN Breox 2000

CN Breox 20M

CN Breox 4000

CN Breox 550

CN Breox PEG 300

CN CAFO 154

CN Carbowax

CN Carbowax 100

CN Carbowax 1000
 CN Carbowax 1350
 CN Carbowax 14000
 CN Carbowax 1500
 CN Carbowax 1540
 CN Carbowax 20
 CN Carbowax 200
 CN Carbowax 20000
 CN Carbowax 25000
 CN Carbowax 300
 CN Carbowax 3350
 CN Carbowax 400
 CN Carbowax 4000
 CN Carbowax 4500
 CN Carbowax 4600

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY

AR 9002-90-8

DR 12676-74-3, 12770-93-3, 9081-95-2, 9085-02-3, 9085-03-4, 54510-95-1,
 125223-68-9, 54847-64-2, 59763-40-5, 64441-68-5, 64640-28-4, 133573-31-6,
 25104-58-9, 25609-81-8, 134919-43-0, 101677-86-5, 99264-61-6, 106186-24-7,
 112895-21-3, 114323-93-2, 50809-04-6, 50809-59-1, 119219-06-6, 60894-12-4,
 61840-14-0, 37361-15-2, 112384-37-9, 70926-57-7, 75285-02-8, 75285-03-9,
 77986-38-0, 150872-82-5, 154394-38-4, 79964-26-4, 80341-53-3, 85399-22-0,
 85945-29-5, 88747-22-2, 34802-42-1, 107502-63-6, 107529-96-4, 116549-90-7,
 156948-19-5, 169046-53-1, 188364-77-4, 188924-03-0, 189154-62-9,
 191743-71-2, 201163-43-1, 206357-86-0, 221638-71-7, 225502-44-3,
 270910-26-4, 307928-07-0, 356055-70-4, 391229-98-4

MF (C2 H4 O)_n H2 O

CI PMS, COM


PCT Polyether

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*,
 DIOGENES, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2,
 HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC,
 PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN,
 USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



69890 REFERENCES IN FILE CA (1957 TO DATE)

17762 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

70151 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 139:46031

REFERENCE 2: 139:45038

REFERENCE 3: 139:44671

REFERENCE 4: 139:44654

REFERENCE 5: 139:44568

REFERENCE 6: 139:44208

REFERENCE 7: 139:43981

REFERENCE 8: 139:43290

REFERENCE 9: 139:43265

REFERENCE 10: 139:42605

L99 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN **15687-27-1** REGISTRY

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-.alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid

CN (.+-.)-2-(p-Isobutylphenyl)propionic acid

CN (.+-.)-Ibuprofen

CN (.+-.)-Ibuprophen

CN (4-Isobutylphenyl)-.alpha.-methylacetic acid

CN (RS)-Ibuprofen

CN (S)-4-Isobutyl-.alpha.-methylphenylacetic acid

CN .alpha.-(4-Isobutylphenyl)propionic acid

CN .alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid

CN 2-(4'-Isobutylphenyl)propionic acid

CN 2-(4-Isobutylphenyl)propanoic acid

CN 2-(p-Isobutylphenyl)propionic acid

CN 4-Isobutyl-.alpha.-methylphenylacetic acid

CN 4-Isobutylhydratropic acid

CN Act 3

CN Adex 200

CN Adran

CN Advil

CN Alaxan

CN Algofen

CN Am-Fam 400

CN Amibufen

CN Anafen

CN Anco

CN Andran

CN Anflagen

CN Antarene

CN Antiflam

CN Apo-Ibuprofen

CN Apsifen

CN Artofen

CN Artril

CN Artril 300

CN Atril 300

CN Balkaprofen

CN Betaprofen

CN Bloom

CN Bluton

CN Brofen

CN Brufanic

CN Brufen

CN Brufen 400

CN Brufen Retard

CN Bruflam

CN Brufort

CN Buburone

CN Burana

CN Butacortelone

CN Butylenin

CN Carol

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS 3D CONCORD

DR 58560-75-1, 139466-08-3

MF C13 H18 O2


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
DIOGENES, DIPPR*, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB,
IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA,
PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2,
USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6324 REFERENCES IN FILE CA (1957 TO DATE)

184 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

6364 REFERENCES IN FILE CAPLUS (1957 TO DATE)

2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:41987

REFERENCE 2: 139:41985

REFERENCE 3: 139:41974

REFERENCE 4: 139:41818

REFERENCE 5: 139:41788

REFERENCE 6: 139:41655

REFERENCE 7: 139:41618

REFERENCE 8: 139:41298

REFERENCE 9: 139:36906

REFERENCE 10: 139:30844

L99 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN 147-24-0 REGISTRY

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8CI)

OTHER NAMES:

CN .beta.-Dimethylaminoethyl benzhydryl ether hydrochloride
CN 2-(Benzhydryloxy)-N,N-dimethylethylamine hydrochloride
CN 2-Diphenylmethoxy-N,N-dimethylethylamine hydrochloride
CN Alledryl
CN Allergan
CN Allergina
CN Allergival
CN Amidryl
CN Bagodryl
CN Bax
CN Bena
CN Bena-Fedrin
CN Benadril hydrochloride
CN Benadryl
CN Benocten
CN Benodine
CN Benylin
CN Benzantin
CN Benzhydramine hydrochloride
CN Benzhydrol .beta.-dimethylaminoethyl ether hydrochloride
CN Denydryl
CN Dibondrin
CN Difenhydramine hydrochloride
CN Dimedrol
CN Dimedrol hydrochloride
CN Diphantine
CN Diphenhydramine hydrochloride
CN Fenylhist
CN Halbmond
CN Histacyl
CN Noctomin
CN Resmin
CN Restamin
CN S 8
CN Sedopretten
CN Sekundal D
CN Syntedril
CN Vena
CN Wehydryl
DR 8052-21-9
MF C17 H21 N O . Cl H
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST,
CIN, CSCHEM, DETHERM*, DIOGENES, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB,
IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHARMASEARCH, PIRA, PROMT,
RTECS*, SPECINFO, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (58-73-1)

Ph2CH-O-CH2-CH2-NMe2

HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1279 REFERENCES IN FILE CA (1957 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1280 REFERENCES IN FILE CAPLUS (1957 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:41788
REFERENCE 2: 139:26674
REFERENCE 3: 139:15273
REFERENCE 4: 139:12826
REFERENCE 5: 138:406923
REFERENCE 6: 138:406917
REFERENCE 7: 138:390926
REFERENCE 8: 138:373970
REFERENCE 9: 138:343878
REFERENCE 10: 138:343856

L99 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN 58-73-1 REGISTRY

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl- (7CI, 8CI)

OTHER NAMES:

CN .alpha.-(2-Dimethylaminoethoxy)diphenylmethane

CN .beta.-Dimethylaminoethanol diphenylmethyl ether

CN .beta.-Dimethylaminoethylbenzhydrylether

CN 2-(Benzhydryloxy)-N,N-dimethylethylamine

CN 2-(Diphenylmethoxy)-N,N-dimethylethylamine

CN Benzhydramine

CN Dimedrol base

CN Diphenhydramine

CN DPH

CN FAR 90X2

CN N-[2-(Diphenylmethoxy)ethyl]-N,N-dimethylamine

CN O-Benzhydryldimethylaminoethanol

CN Probedryl

FS 3D CONCORD

MF C17 H21 N O

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Ph₂CH-O-CH₂-CH₂-NMe₂

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3008 REFERENCES IN FILE,CA (1957 TO DATE)
62 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3018 REFERENCES IN FILE CAPLUS (1957 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:46005
REFERENCE 2: 139:41851
REFERENCE 3: 139:41788
REFERENCE 4: 139:26674
REFERENCE 5: 139:17578
REFERENCE 6: 139:17066
REFERENCE 7: 139:6872
REFERENCE 8: 138:396066
REFERENCE 9: 138:395915
REFERENCE 10: 138:390926

=> fil wpix
FILE 'WPIX' ENTERED AT 17:26:36 ON 16 JUL 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 16 JUL 2003 <20030716/UP>
MOST RECENT DERWENT UPDATE: 200345 <200345/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> NEW WEEKLY SDI FREQUENCY AVAILABLE --> see NEWS <<<

>>> SLART (Simultaneous Left and Right Truncation) is now
available in the /ABEX field. An additional search field
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot

L129 ANSWER 1 OF 3 WPIX (C) 2003 THOMSON DERWENT

AN 2002-590698 [63] WPIX

DNC C2002-167152

TI Composition useful for treating pain-associated sleep
disturbances comprises **ibuprofen** and **diphenhydramine**.

DC B05

IN BIANCO, J; COOK, G D; COOPER, S; DOYLE, G; FORT, J J; GIALMALVA, D H; KOCH,

T S; BIANCO, G; COOPER, S A; DOYLE, G A
 PA (BIAN-I) BIANCO J; (COOK-I) COOK G D; (COOP-I) COOPER S; (DOYL-I) DOYLE G;
 (FORT-I) FORT J J; (GIAM-I) GIAMALVA'D H; (KOCH-I) KOCH T S; (AMHP) WYETH
 CYC 100
 PI WO 2002056877 A1 20020725 (200263)* EN 75p A61K031-00
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
 US 2002177626 A1 20021128 (200281) A61K031-19
 ADT WO 2002056877 A1 WO 2002-US3855 20020118; US 2002177626 A1 Provisional US
 2001-262387P 20010119, US 2002-46727 20020117
 PRAI US 2001-262387P 20010119; US 2002-46727 20020117
 IC ICM A61K031-00; A61K031-19
 ICS A61K031-135
 AB WO 200256877 A UPAB: 20021001
 NOVELTY - A composition comprises **ibuprofen** (I) and
diphenhydramine (II).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for
 evaluating a compound or composition for the treatment of a
 pain-associated **sleep** disturbance in patients experiencing at
 least moderate or several levels of pain involving:

- (a) administering the compound or composition to the patient after
 oral surgery;
 - (b) sending the patient to bed earlier than his usual bedtime; and
 - (c) assessing the effectiveness of the compound or the composition.
- ACTIVITY - Analgesic; Sedative.

Patients suffering from pain associated **sleep** disturbances
 were administered **ibuprofen** (400 mg) and **diphenhydramine**
 (50 mg) in a single soft gelatin **capsule** before bedtime. The
 symptoms of their pain associated **sleep** disturbances improved.
 They slept for a longer duration and also fell asleep faster than
 expected. Thus the composition was useful for treating pain associated
sleep disturbances.

MECHANISM OF ACTION - None given.

USE - For treating pain-associated **sleep** disturbances
 affecting **sleep** duration (claimed) (preferably shortened
sleep duration). The pain-associated **sleep** disturbances
 include difficulties in falling asleep and staying asleep.

ADVANTAGE - The composition does not have negative interactions
 between (I) and (II) during formulation or when placed on shelves. The
 composition is stable chemically and physically. The combination of (I)
 and (II) yields a somnolent effect greater than that of (II) alone. (I)
 Alone is effective for only 4-6 hours while the composition is effective
 for longer periods of time.

Dwg.0/29

FS CPI

FA AB; DCN

MC CPI: B10-B03B; B10-C02; B10-C04C; B11-C08; B12-K04; **B12-M11B;**
B12-M11C; B12-M11K; B14-C01; B14-J01B1

TECH UPTX: 20021001

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The
 composition comprises (I) (50-800, preferably 200 mg) and (II) in the form
 of **diphenhydramine HCl** (12.5-50, preferably 25 mg) or
diphenhydramine citrate (19-38, preferably 38 mg).
 Preferred Method: The step (c) is performed by evaluating at least one of
sleep latency, sum of pain relief and pain intensity differences
 over 0-3 hours (SPRID3), cumulative percent asleep at 60 minutes, ease of
 falling asleep, duration of **sleep**, global evaluation of
sleep, median time to rescue medication, percent of patients
 requiring rescue medication, global assessment as a pain reliever, global

assessment as a **sleep** acid or pain relief intensity difference (PRID) 90 or 60 minutes (preferably **sleep** latency, **sleep** duration and SPRID3). The patient is sent to bed 1-6 (preferably at least 1, 3 or upto 6) hours earlier than his usual bedtime.

ABEX UPTX: 20021001

ADMINISTRATION - Administration of (I) is 50-800 (preferably 200) mg. The dosage for **diphenhydramine HCl** is 12.5-50 (preferably 25) mg and that for **diphenhydramine citrate** is 19-38 (preferably 38) mg. The composition is a bilayer **tablet** or **caplet** or a soft gelatin **capsule** containing **polyethylene glycol** and is administered in one or two doses concomitantly. The second dose is optionally administered (all claimed). The composition is administered from 90 minutes before bedtime to immediately before bedtime (preferably 45-15 minutes especially 30 minutes before bedtime).

EXAMPLE - **Diphenhydramine hydrochloride** (40.050 kg) was dissolved in water (46.138 kg) and **polyethylene glycol** (molecular weight 600) (200.250 kg) was added to it. **Polyethylene glycol** (molecular weight 600) (326.808 kg) was also added to **ibuprofen** (320.400 kg) and mixed. Potassium hydroxide (41.011 kg) was dissolved in water (34.603 kg) and added to the **ibuprofen** dispersion and mixed under vacuum. The temperature was maintained at 75-125 degrees F. The **diphenhydramine hydrochloride** solution was added to the **ibuprofen** /potassium hydroxide/**polyethylene glycol** solution and mixed under vacuum. The solution was deaerated under vacuum for at least 15 minutes and pressurized. The solution was **encapsulated** with in a gelatin shell and processed to completion. The **capsule** had the following composition (mg): **ibuprofen** (200), **diphenhydramine HCl** (25), DandC Red No. 33 (RTM) (0.0113), FDandC Blue No.1 (RTM) (0.0170), **polyethylene glycol** (molecular weight 600) (329), potassium hydroxide (25.6), purified water (50.4), ANDRISORB 85/70 (RTM) (93.4) and gelatin (164).

L129 ANSWER 2 OF 3 WPIX (C) 2003 THOMSON DERWENT

AN 2001-290269 [30] WPIX

DNC C2001-088857

TI Liquid softgel fill formulations comprising high concentrations of **ibuprofen** in free form, and **capsules** containing them.

DC A14 A25 A96 B05 B07

IN GULLAPALLI, R P

PA (BANN-N) BANNER PHARMACAPS INC

CYC 95

PI WO 2001015688 A1 20010308 (200130)* EN 20p A61K031-19

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2000070949 A 20010326 (200137) A61K031-19

US 6251426 B1 20010626 (200138) A61K009-48 <--

EP 1207872 A1 20020529 (200243) EN A61K031-19

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI

JP 2003508434 W 20030304 (200319) 21p A61K031-192

ADT WO 2001015688 A1 WO 2000-US23908 20000901; AU 2000070949 A AU 2000-70949
20000901; US 6251426 B1 US 1999-389003 19990902; EP 1207872 A1 EP
2000-959667 20000901, WO 2000-US23908 20000901; JP 2003508434 W WO
2000-US23908 20000901, JP 2001-519902 20000901

FDT AU 2000070949 A Based on WO 200115688; EP 1207872 A1 Based on WO
200115688; JP 2003508434 W Based on WO 200115688

PRAI US 1999-389003 19990902
 IC ICM **A61K009-48**; A61K031-19; A61K031-192
 ICS **A61K009-06**; **A61K009-58**; **A61K009-64**;
A61K009-66; A61K045-00; A61K047-14; A61K047-22; A61K047-32;
 A61K047-34; A61P029-00
 AB WO 200115688 A UPAB: 20010603
 NOVELTY - Stable liquid softgel fill formulations comprising high concentrations of **ibuprofen** in free form, **polyethylene glycol** and polyvinylpyrrolidone, and soft gelatin **capsules** containing them, are new.
 DETAILED DESCRIPTION - A liquid softgel fill formulation comprises (as wt.%):
 (a) greater than 30% **ibuprofen** (I) in free acid form in solution;
 (b) 30-60% **polyethylene glycol** (PEG);
 (c) 10-30% polyvinylpyrrolidone (PVP); and
 (d) optionally 1-10% surfactant to increase bioavailability of (I).
 INDEPENDENT CLAIMS are included for softgel **capsules** comprising a sheath enclosing a liquid fill as described above.
 USE - For administration of **ibuprofen**.
 ADVANTAGE - Use of a large amount of PVP permits a reduction in the amount of **PEG** required, reducing the esterification reaction between (I) and **PEG**.
 Dwg.0/0
 FS CPI
 FA AB; DCN
 MC CPI: A03-C01; A04-D05A; A05-H04; A12-V01; B04-C03C; B10-C04C; B12-M07;
B12-M11C
 TECH UPTX: 20010603
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition preferably comprises at least 35 wt.% (I); 30-50% **PEG** having average molecular weight (MW) 200-1,000; and 15-30% PVP having MW 2,000-54,000. The surfactant is e.g. an ester of d-alpha-tocopheryl, a **polyoxyethylene** castor oil derivative, or polyglycolized glyceride.
 The composition may further comprise up to 6% of a nasal decongestant (e.g. pseudoephedrine hydrochloride), or up to 10% of an antihistaminic (e.g. **diphenhydramine hydrochloride**).
 The sheath of the softgel **capsule** comprises 45-75% gelatin; 20-40% plasticizer (e.g. sorbitol, sorbitol special, and/or maltitol); and 5-15% water. The total weight of the **capsule** fill is less than 600 mg, and the weight of (I) is at least 200 mg.
 ABEX UPTX: 20010603
 EXAMPLE - A fill formulation was prepared comprising (as wt.%): (I) 35%; **PEG** 600 37%; Kollidon17 PF (RTM: PVP, MW 10,000) 22%; and Vitamin E TPGS 6%.
 L129 ANSWER 3 OF 3 WPIX (C) 2003 THOMSON DERWENT
 AN **1997-369376** [34] WPIX
 DNC **C1997-118673**
 TI Cold remedy soft **capsule** - comprises solution of **ibuprofen** and second drug e.g. histamine antagonist.
 DC A96 B05
 PA (RPSE-N) RP SEALER KK; (SATO) SATO SEIYAKU KK
 CYC 1
 PI JP 09157162 A 19970617 (199734)* 12p A61K031-19
 JP 3382076 B2 20030304 (200319) 10p A61K031-19
 ADT JP 09157162 A JP 1995-322706 19951212; JP 3382076 B2 JP 1995-322706 19951212
 FDT JP 3382076 B2 Previous Publ. JP 09157162
 PRAI JP 1995-322706 19951212
 IC ICM A61K031-19
 ICS **A61K009-08**; **A61K009-48**; A61K031-52; A61K045-00;

A61K045-06; A61K047-14; A61K047-34; A61P011-10; A61P011-14;
 A61P025-02; A61P025-04; A61P025-20; A61P025-26; A61P029-00;
 A61P043-00

ICI A61K031-19, A61K045:06

AB JP 09157162 A UPAB: 19970820

A cold remedy soft **capsule** comprises a soln. of **ibuprofen** and one or more second drugs from histamine antagonist, antitussive agent, expectorant, sympathetic nerve stimulant and central stimulant in a base contg. a surfactant from **polyoxyethylene** (POE) sorbitan fatty acid ester, POE hardened castor oil and polyglycerol fatty acid ester and water, and no hydroxide ions.

The central stimulant is anhydrous caffeine, caffeine or sodium benzoate caffeine.

The surfactant has HLB of 13-18.

POE (20) sorbitan monooleate (1030.5g) at about 60 deg.C was added with **ibuprofen** (225g), **diphenhydramine hydrochloride** (37.5g), dihydrocodeine phosphate (12b), noscapine hydrochloride (24mg), dl-methylephedrine hydrochloride (30g), guaifenesin (125g) and anhydrous caffeine (15g). The mixt. was vigorously stirred using a homogenizer, cooled to about 40 deg.C, added with purified water (106g), deaerated under vacuum and filtered through a 100 mesh. The filtrate (each 535mg) was filled in a gelatin film [comprising gelatin (100g) and glycerol (30g)] to give 3,000 soft **capsules**.

ADVANTAGE - Absorption of the drugs is excellent, **ibuprofen** is stable in the **capsule**, and the **capsule** need not be measured and is handy to carry.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: A10-E07; A12-V01; B04-A04; B04-A06; B04-A10; B04-N02; B05-A01B;
 B10-B03B; B10-C04C; B12-M09; **B12-M11C**; B14-C04; B14-L09

=> d his

(FILE 'HOME' ENTERED AT 16:42:01 ON 16 JUL 2003)
 SET COST OFF

L1 FILE 'HCAPLUS' ENTERED AT 16:42:20 ON 16 JUL 2003
 1 S US20020177626/PN

FILE 'HCAPLUS' ENTERED AT 16:42:57 ON 16 JUL 2003
 S 15687-27-1/REG#

FILE 'REGISTRY' ENTERED AT 16:42:57 ON 16 JUL 2003

FILE 'HCAPLUS' ENTERED AT 16:42:57 ON 16 JUL 2003
 S 58-73-1/REG#

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 16 JUL 2003

FILE 'HCAPLUS' ENTERED AT 16:42:58 ON 16 JUL 2003

L2 FILE 'REGISTRY' ENTERED AT 16:43:10 ON 16 JUL 2003
 1 S 15687-27-1
 L3 1 S 58-73-1
 L4 1 S 25322-68-3
 L5 137 S C13H18O2/MF AND 46.150.18/RID AND BENZENEACETIC
 L6 3 S L5 AND IBUPROFEN
 L7 3 S L2, L6
 L8 209 S 58-73-1/CRN
 SEL RN L7
 L9 313 S E1-E3/CRN

L10 4 S L8 AND L9
L11 1 S L10 AND 2/NC
L12 110 S L8 NOT (MXS OR IDS OR PMS)/CI
L13 29 S L12 NOT (UNSPECIFIED OR COMPD OR WITH)
L14 26 S L13 NOT SALT
L15 23 S L14 NOT (CONJUGATE OR CR/ELS)
L16 3 S L13 NOT L14
L17 26 S L15,L16
L18 1 S L17 AND CLH
L19 2 S L17 AND C6H8O7
L20 3 S L18,L19
L21 23 S L17 NOT L20
L22 44 S L9 NOT ((MXS OR IDS OR PMS)/CI OR UNSPECIFIED OR COMPD OR WI
L23 41 S L22 NOT (LYSINE OR CYCLODEXTRIN OR TETRAKIS)

FILE 'HCAPLUS' ENTERED AT 16:51:26 ON 16 JUL 2003

L24 1 S L11
L25 6751 S L7 OR L23
L26 7215 S IBUPROFEN
L27 27 S DEXIBUPROFEN
L28 140 S 2 4 ISOBUTYLPHENYL PROPIONIC ACID
L29 39 S 2 P ISOBUTYLPHENYL PROPIONIC ACID
L30 8206 S L25-L29
L31 1294 S L20 OR L21
L32 4208 S DIPHENHYDRAMINE
L33 16 S DIPHENHYDRAMINE CITRATE
L34 527 S DIPHENHYDRAMINE HYDROCHLORIDE
L35 459 S DIPHENHYDRAMINE (A) HCL
L36 535 S DIMEDROL
L37 5035 S L31-L36
L38 227 S L30 AND L37
L39 33 S L38 AND L4
L40 33 S L38 AND (PEG OR POLYETHYLENEGLYCOL OR POLYETHYLENEOXIDE OR PO
L41 0 S L38 AND POLY() (ETHYLENEGLYCOL OR ETHYLENEOXIDE OR ETHYLENE() (
L42 40 S L39,L40
L43 23 S L38 AND POLYOXYALKYLENE
L44 42 S L42,L43
L45 1 S L44 AND SLEEP?
E SLEEP/CT
L46 7983 S E3-E10
E E3+ALL
L47 8142 S E2+NT
L48 1580 S E3,E4/BI
L49 1 S L44 AND L46-L48
L50 1 S L38 AND L46-L48
L51 1 S L38 AND SLEEP?
E INSOMNIA/CT
L52 570 S E3,E4
E E3+ALL
L53 0 S L38 AND L52
L54 0 S L38 AND INSOMN?
L55 1 S L49-L51
L56 3046 S L3
L57 197 S L56 AND L30
L58 1 S L57 AND SLEEP?
L59 0 S L57 AND INSOMN?
L60 1 S L57 AND L46-L48
L61 1 S L55,L58,L60
L62 257 S L38,L57
L63 19 S L62 AND PAIN?
L64 76 S L62 AND ANALGE?
E PAIN/CT
E E3+ALL

L65 86 S L62 AND (E3+NT OR E5+NT OR E6+NT OR E7+NT OR E8+NT OR E9+NT O
 L66 98 S L63-L65
 L67 229 S L62 AND (PD<=20010119 OR PRD<=20010119 OR AD<=20010119)
 L68 87 S L67 AND L66
 L69 28 S L67 AND L4
 L70 27 S L67 AND (PEG OR POLYETHYLENEGLYCOL OR POLYETHYLENEOXIDE OR PO
 L71 0 S L67 AND POLY() (ETHYLENEGLYCOL OR ETHYLENEOXIDE OR ETHYLENE() (
 L72 15 S L67 AND POLYOXYALKYLENE
 L73 34 S L69-L72
 E COOPER S/AU
 L74 116 S E3,E4
 E COOPER STEVE/AU
 L75 5 S E3,E5
 E COOPER STEPHEN/AU
 L76 88 S E3-E5
 E COOK G/AU
 L77 41 S E3,E8,E9
 E COOK GRAHAM/AU
 L78 9 S E3-E5
 E KOCH T/AU
 L79 73 S E3,E10
 E KOCH TODD/AU
 L80 3 S E4,E5
 E GIALMALVA D/AU
 L81 26 S E3-E6
 E BIANCO J/AU
 L82 21 S E3-E7
 L83 1 S E19
 E FORT J/AU
 L84 52 S E3,E8-E11
 E DOYLE G/AU
 L85 59 S E3-E11
 L86 7 S E38-E40
 L87 1 S L74-L86 AND L62
 L88 2 S WYETH?/PA,CS AND L62
 L89 2 S L61,L87,L88
 L90 1 S L73 AND L89
 L91 2 S L89,L90
 L92 3 S L24,L91
 L93 33 S L73 NOT L92
 L94 11 S L93 AND (?CAPSUL? OR ?CAPLET? OR ?TABLET?)
 L95 22 S L93 NOT L94
 SEL DN AN 7
 L96 1 S L95 AND E1-E3
 SEL DN AN L94 2
 L97 1 S L94 AND E4-E6
 L98 5 S L92,L96,L97

FILE 'HCAPLUS' ENTERED AT 17:09:43 ON 16 JUL 2003
 SEL HIT RN L98

FILE 'REGISTRY' ENTERED AT 17:09:58 ON 16 JUL 2003
 L99 6 S E7-E12

FILE 'WPIX' ENTERED AT 17:10:07 ON 16 JUL 2003
 L100 1751 S L26/BIX OR L27/BIX OR L28/BIX OR L29/BIX
 E IBUPROFEN/DCN
 E E3+ALL
 L101 1701 S E2 OR 1987/DRN
 L102 3 S E4
 L103 556 S E8
 L104 15 S E10
 L105 5 S E14

L106 33 S E20
L107 2279 S L100-L106
L108 496 S L32/BIX OR L33/BIX OR L34/BIX OR L35/BIX OR L36/BIX
E DIPHENHYDRAMINE/DCN
E E3+ALL
L109 501 S E2 OR 0170/DRN
L110 164 S E4
L111 139 S L107 AND L108-L110
E R02044+ALL/DCN
L112 7674 S E1 OR 2044/DRN
L113 47628 S (PEG OR POLYETHYLENEGLYCOL OR POLYETHYLENEOXIDE OR POLYOXYETH
L114 2062 S (POLY() (ETHYLENEGLYCOL OR ETHYLENEOXIDE OR ETHYLENE) () (GLYCOL
L115 32310 S (POLYETHYLENE() (GLYCOL OR OXIDE) OR POLYOXY ETHYLENE OR POLY
L116 35 S L111 AND L112-L115
L117 16 S L116 AND (?CAPSUL? OR ?CAPLET? OR ?TABLET?)/BIX
L118 10 S L116 AND (R031 OR R033 OR R034 OR R038)/M0,M1,M2,M3,M4,M5,M6
L119 14 S L116 AND (B12-M11 OR B12-M11A OR B12-M11B OR B12-M11C OR B12-
L120 0 S L116 AND (C12-M11 OR C12-M11A OR C12-M11B OR C12-M11C OR C12-
L121 17 S L117-L119
L122 18 S L116 NOT L121
L123 27 S L116 AND A61K009/IC, ICM, ICS, ICA, ICI
L124 15 S L123 AND L121
L125 17 S L121, L124
L126 12 S L123 NOT L125
L127 1 S L125 AND SLEEP?/BIX
L128 17 S L125, L127 AND M782/M0, M1, M2, M3, M4, M5, M6
SEL DN AN 5 8 11
L129 3 S L128 AND E1-E6

FILE 'WPIX' ENTERED AT 17:26:36 ON 16 JUL 2003